Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084669 · ClinicalTrials.gov registry record · NA
Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 119
- Enrollment target
NCT00084669: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00084669 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084669, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
Study Summary
RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy. Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in women who are receiving hormone therapy for treatment or prevention of breast cancer. PURPOSE: This randomized clinical trial is studying giving venlafaxine together with zolpidem to see how well it works compared to venlafaxine alone in relieving hot flashes and associated sleep disorders in women who are receiving hormone therapy to treat or prevent breast cancer.
Interventions
- DRUG venlafaxine
- PROCEDURE management of therapy complications
- DRUG zolpidem tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2004-05 |
| Est. Completion | 2010-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084669
The ClinicalTrials.gov registry entry for NCT00084669 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which venlafaxine is the first listed.
NCT00084669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084669 about?
NCT00084669 is a clinical study titled "Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer". RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy. Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in women who are receiving hormone therapy for treatment or prevention of breast cancer. PURPOSE: This randomized clin...
What is the current status of trial NCT00084669?
This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2004-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00084669?
The interventions under investigation include: venlafaxine (DRUG), management of therapy complications (PROCEDURE), zolpidem tartrate (DRUG).
Who is sponsoring clinical trial NCT00084669?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.